Search

Your search keyword '"Parameshwar, J."' showing total 443 results
Start Over Author "Parameshwar, J."
443 results on '"Parameshwar, J."'

101. Cancer gene therapy

Author

Donald J. Buchsbaum, C. Ryan Miller, Parameshwar J. Mahasreshti, and David T. Curiel

Published
2003

102. Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix

Author

Jialing Xiang, David T. Curiel, Mack N. Barnes, Waleed Arafat, Jesus Gomez-Navarro, Warner K. Huh, Parameshwar J. Mahasreshti, and Ronald D. Alvarez

Subjects
Pathology, medicine.medical_specialty, Programmed cell death, Genetic enhancement, Genetic Vectors, Uterine Cervical Neoplasms, Apoptosis, Viral vector, Adenoviridae, Transduction, Genetic, Proto-Oncogene Proteins, medicine, Carcinoma, Tumor Cells, Cultured, Humans, Genes, Tumor Suppressor, Cervix, bcl-2-Associated X Protein, Cervical cancer, business.industry, Obstetrics and Gynecology, Genetic Therapy, medicine.disease, medicine.anatomical_structure, Oncology, Proto-Oncogene Proteins c-bcl-2, Cell culture, Cancer research, Female, business, HeLa Cells
Abstract

Objective. The transfer of tumor suppresser genes has been shown to revert the malignant phenotype. In this regard, bax is a pro-apoptotic molecule that also functions as a tumor suppresser. The purpose of this study was to evaluate bax as a gene therapeutic in the context of cervical cancer. Methods. Efficiency of viral transduction in cervical cancer cell lines and primary cervical cancer cells was evaluated with an adenoviral vector encoding green fluorescent protein and luciferase, respectively. We generated a recombinant adenoviral vector that encodes the bax gene under inducible conditions. To this end, expression of this pro-apoptotic gene was controlled by a Cre-LoxP system. Following infection with the recombinant bax adenovirus, the viability of cervical cancer cell lines and primary cervical cancer cells was evaluated using crystal violet staining and FACS analysis. Apoptotic cell death was monitored using annexin V staining. Results. High levels of viral infection were observed in all cervical cancer cell lines (>85%) and primary cervical cancer cells. Significant cytotoxicity was seen in all cervical cancer cells lines and, more importantly, patient-derived primary cervical cancer cells. Moreover, bax -mediated cell death occurred via an apoptotic pathway. Conclusions. Our results indicate that a bax recombinant adenoviral vector causes cell death mediated via an apoptotic pathway in multiple cervical cancer cell lines and primary cervical cancer cells. These data suggest that bax may be a candidate for human gene therapy in the setting of cervical carcinoma.

Published
2001

103. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites

Author

David T. Curiel, Enrique Casado, Shannon D. Barker, Jesus Gomez-Navarro, Akseli Hemminki, Waleed Arafat, Parameshwar J. Mahasreshti, Gene P. Siegal, Terri B. Pustilnik, Ronald D. Alvarez, and Jialing Xiang

Subjects
Pathology, medicine.medical_specialty, medicine.drug_class, Cytodiagnosis, Ovary, Monoclonal antibody, Dynabeads, Ovarian tumor, Antigens, Neoplasm, medicine, Biomarkers, Tumor, Tumor Cells, Cultured, Ascitic Fluid, Humans, Glycoproteins, Ovarian Neoplasms, biology, business.industry, Immunomagnetic Separation, Obstetrics and Gynecology, Antibodies, Monoclonal, Primary and secondary antibodies, medicine.anatomical_structure, Oncology, Cell culture, Cancer cell, biology.protein, Cancer research, Female, Tumor-associated glycoprotein 72, business
Abstract

Objective. Primary ovarian cancer cells obtained from fresh tumor have many advantages over established cell lines. Therefore, a procedure for the specific and efficient purification of such neoplastic cells is critical. We report an effective immunomagnetic method for the isolation of tumor cells from the ascitic fluid of patients diagnosed with ovarian adenocarcinoma. Methods. This procedure incorporates the use of monoclonal antibody (mAb) CC49, which recognizes the tumor-associated glycoprotein 72 (TAG-72). TAG-72 is highly expressed on ovarian tumor cell surfaces with little or no reactivity with normal tissues. Also used in this protocol are immunomagnetic beads, which bind to the CC49 mAb via a secondary antibody. When ovarian cancer cells adhere to the magnetic beads, a magnetic field is used to separate the tumor cells from all other cellular components. Results. Using ascitic fluid from five patients, we found that preparations before purification contained between 38 and 52% neoplastic cells. Using our method, we produced preparations that were between 63 and 96% pure for cancer cells, thus obtaining an average increase in tumor cell enrichment of 86%. Conclusion. We, therefore, believe this method is preferable for producing high yields of pure ovarian neoplastic cells. We are now employing this technique in our laboratory to provide a stringent and pure template for our studies on gene transfer to primary ovarian cancer cells.

Published
2001

105. Everolimus Prevents the Quilty Phenomenon – A Risk Factor for Microvasculopathy in Biopsy (RAD B253 Trial)

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique, Hiemann, N.E., Bara, C., Segovia, J., Parameshwar, J., Simonsen, S., Crespo-Leiro, M., Eiskjaer, H., Vanhaecke, J., Arizon, J.M., Poncelet, Alain, Przybylowski, P., Frigerio, M., Lehmkuhl, H., Meyer, R., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique, Hiemann, N.E., Bara, C., Segovia, J., Parameshwar, J., Simonsen, S., Crespo-Leiro, M., Eiskjaer, H., Vanhaecke, J., Arizon, J.M., Poncelet, Alain, Przybylowski, P., Frigerio, M., Lehmkuhl, H., and Meyer, R.

Published
2011

106. Effect of everolimus and donor/recipient serology on cytomegalovirus infection in heart transplant recipients: A subanalysis of the ranomized trial A2310

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique, Potena, L, Pellegrini, C, Musumeci, F, Parameshwar, J, Dong, G, Lopez, P, Poncelet, Alain, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique, Potena, L, Pellegrini, C, Musumeci, F, Parameshwar, J, Dong, G, Lopez, P, and Poncelet, Alain

Published
2011

107. Everolimus for the Prevention of Microvasculopathy in Biopsy: Final Results from Re-Evaluation of the RAD B253 Trial

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique, Hiemann, N.E., Bara, C., Segovia, J., Parameshwar, J., Simonsen, S., Crespo-Leiro, M., Eiskjaer, H., Vanhaecke, J., Arizon, J.M., Poncelet, Alain, Przybylowski, P., Frigerio, M., Lehmkuhl, H., Meyer, R., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de chirurgie cardiovasculaire et thoracique, Hiemann, N.E., Bara, C., Segovia, J., Parameshwar, J., Simonsen, S., Crespo-Leiro, M., Eiskjaer, H., Vanhaecke, J., Arizon, J.M., Poncelet, Alain, Przybylowski, P., Frigerio, M., Lehmkuhl, H., and Meyer, R.

Published
2011

112. Utility of Gene Expression Profiling Test (GEP) Score Instability To Predict Future Clinical Outcomes in Heart Transplant: Results from the CARGO 2 European-Based Multicenter Trial

Author

Crespo-Leiro, M.G., primary, Stypmann, J., additional, Zuckermann, A., additional, Bara, C., additional, Ross, H., additional, Parameshwar, J., additional, Zakliczynski, M., additional, Fiocchi, R., additional, Hoefer, D., additional, Hiemann, N., additional, Leprince, P., additional, Deng, M.C., additional, Hiller, D., additional, Yee, J.P., additional, and Vanhaecke, J., additional

Published
2013
Full Text
View/download PDF

117. 81 Prediction of Allograft Clinical Outcomes and Risk of Acute Cellular Rejection with a Non-Invasive Gene-Expression Profiling Test (AlloMap): Results from the Cargo 2 European-Based Multicenter Trial

Author

Crespo-Leiro, M.G., primary, Schulz, U., additional, Zuckermann, A., additional, Bara, C., additional, Mohacsi, P., additional, Bogaev, R., additional, Boyle, A., additional, Ross, H., additional, Parameshwar, J., additional, Zakliczynski, M., additional, Fiocchi, R., additional, Stypmann, J., additional, Hoefer, D., additional, Lehmkuhl, H., additional, Deng, M.C., additional, Leprince, P., additional, Yee, J.P., additional, and Vanhaecke, J., additional

Published
2012
Full Text
View/download PDF

118. UK guidelines for referral and assessment of adults for heart transplantation

Author

Banner, N. R., primary, Bonser, R. S., additional, Clark, A. L., additional, Clark, S., additional, Cowburn, P. J., additional, Gardner, R. S., additional, Kalra, P. R., additional, McDonagh, T., additional, Rogers, C. A., additional, Swan, L., additional, Parameshwar, J., additional, Thomas, H. L., additional, and Williams, S. G., additional

Published
2011
Full Text
View/download PDF

120. 205 Everolimus Prevents the Quilty Phenomenon – A Risk Factor for Microvasculopathy in Biopsy (RAD B253 Trial)

Author

Hiemann, N.E., primary, Bara, C., additional, Segovia, J., additional, Parameshwar, J., additional, Simonsen, S., additional, Crespo-Leiro, M., additional, Eiskjaer, H., additional, Vanhaecke, J., additional, Arizon, J.M., additional, Poncelet, A., additional, Przybylowski, P., additional, Frigerio, M., additional, Lehmkuhl, H., additional, and Meyer, R., additional

Published
2011
Full Text
View/download PDF

123. 76 Everolimus for the Prevention of Microvasculopathy in Biopsy: Final Results from Re-Evaluation of the RAD B253 Trial

Author

Hiemann, N.E., primary, Bara, C., additional, Segovia, J., additional, Parameshwar, J., additional, Simonsen, S., additional, Crespo-Leiro, M., additional, Eiskjaer, H., additional, Vanhaecke, J., additional, Arizon, J.M., additional, Poncelet, A., additional, Przybylowski, P., additional, Frigerio, M., additional, Lehmkuhl, H., additional, and Meyer, R., additional

Published
2011
Full Text
View/download PDF

127. 473: Inter-Observer Variability in the Interpretation of Cardiac Biopsies Remains a Challenge: Results of the Cardiac Allograft Rejection Gene Expression Observational (CARGO) II Study

Author

Crespo-Leiro, M.G., primary, Schulz, U., additional, Vanhaecke, J., additional, Zuckermann, A., additional, Bara, C., additional, Mohacsi, P., additional, Bogaev, R.C., additional, Boyle, A., additional, Ross, H., additional, Parameshwar, J., additional, Zakliczynski, M., additional, Fiocchi, R., additional, Stypmann, J., additional, Hoefer, D., additional, Lehmkuhl, H., additional, Deng, M.C., additional, Leprince, P., additional, Berry, G., additional, Marboe, C.C., additional, Stewart, S., additional, Tazelaar, H.D., additional, Brown, M., additional, and Baron, H.M., additional

Published
2009
Full Text
View/download PDF

130. Heart failure in a district general hospital

Author

Parameshwar, J., Poole-Wilson, P. A., and Sutton, G. C.

Subjects
Cardiomyopathy, Dilated, Heart Defects, Congenital, Heart Failure, Male, Heart Valve Diseases, Angiotensin-Converting Enzyme Inhibitors, Coronary Disease, Pulmonary Edema, Length of Stay, Middle Aged, Hospitals, District, Hospitals, General, Prognosis, Original Papers, Hyperthyroidism, Pulmonary Heart Disease, Hypertension, London, Humans, Female, Prospective Studies, Diuretics, Letters to the Editor, Aged
Abstract

The frequency, clinical characteristics, and outcome of patients admitted with heart failure to a district general hospital in North-West London serving a population of approximately 155,000 was assessed over a six-month period. The number of patients with heart failure was determined by both a prospective ward survey and a retrospective study of all patient records with diagnostic codes for heart failure or pulmonary oedema. During those six months, 2,877 patients were admitted to the medical and geriatric services of whom 140 (4.9%) had heart failure. Only 29 patients in heart failure were under the age of 65 years. In 86 patients the mode of presentation was acute pulmonary oedema. Fifty-two (37%) patients had an arrhythmia at the time of admission of whom 48 had atrial fibrillation. An electrocardiogram, a chest X-ray, and an echocardiogram were performed in 137, 136, and 81 patients respectively. The aetiology of heart failure was considered to be coronary artery disease (41%), valve disease (9%), hypertension (6%), cor pulmonale (4%), a dilated cardiomyopathy (1%), congenital heart disease (1%), thyrotoxicosis (1%), and unknown (36%). During the period of hospital stay 42 patients (30%) died; a further 20 patients (14%) died in a one-year follow-up. In a district general hospital heart failure is a common reason for admission and patients remain in hospital for a considerable time. Arrhythmias are commonly associated with heart failure. The prognosis is poor and the hospital mortality high. The management of heart failure is an important consideration in allocating hospital resources in a district general hospital.

Published
1992

137. Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy

Author

Mahasreshti, Parameshwar J., primary, Kataram, Manjula, additional, Wu, Hongju, additional, Yalavarthy, Laxmi Priya, additional, Carey, Delicia, additional, Dent, Paul, additional, Chada, Sunil, additional, Alvarez, Ronald D., additional, Haisma, Hidde J., additional, Fisher, Paul B., additional, and Curiel, David T., additional

Published
2006
Full Text
View/download PDF

141. A NovelEx vivoModel System for Evaluation of Conditionally Replicative Adenoviruses Therapeutic Efficacy and Toxicity

Author

Kirby, Tyler O., primary, Rivera, Angel, additional, Rein, Daniel, additional, Wang, Minghui, additional, Ulasov, Ilya, additional, Breidenbach, Martina, additional, Kataram, Manjula, additional, Contreras, Juan L., additional, Krumdieck, Carlos, additional, Yamamoto, Masato, additional, Rots, Marianne G., additional, Haisma, Hidde J., additional, Alvarez, Ronald D., additional, Mahasreshti, Parameshwar J., additional, and Curiel, David T., additional

Published
2004
Full Text
View/download PDF

142. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor

Author

Mahendra, Gandham, primary, Kumar, Sanjay, additional, Isayeva, Tatyana, additional, Mahasreshti, Parameshwar J, additional, Curiel, David T, additional, Stockardt, Cecil R, additional, Grizzle, William E, additional, Alapati, Vidya, additional, Singh, Raj, additional, Siegal, Gene P, additional, Meleth, Sreelatha, additional, and Ponnazhagan, Selvarangan, additional

Published
2004
Full Text
View/download PDF

144. Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma

Author

Leath, Charles A, primary, Kataram, Manjula, additional, Bhagavatula, Pradeep, additional, Gopalkrishnan, Rahul V, additional, Dent, Paul, additional, Fisher, Paul B, additional, Pereboev, Alexander, additional, Carey, Delicia, additional, Lebedeva, Irina V, additional, Haisma, Hidde J, additional, Alvarez, Ronald D, additional, Curiel, David T, additional, and Mahasreshti, Parameshwar J, additional

Published
2004
Full Text
View/download PDF

149. 1017. Selective Induction of Tumor-Associated Antigens in Murine Pulmonary Vasculature Using Double-Targeted Adenoviral Vectors

Author

Michael J. Passineau, Paul N. Reynolds, SangAe Kim-Park, Meredith A. Preuss, Alexander Pereboev, Joel N. Glasgow, William E. Grizzle, Parameshwar J. Mahasreshti, Maaike Everts, and David T. Curiel

Subjects
Pharmacology, Transgene, Biology, Molecular biology, Viral vector, Carcinoembryonic antigen, Antigen, Drug Discovery, Genetics, Systemic administration, Transcriptional regulation, biology.protein, Molecular Medicine, Luciferase, Receptor, Molecular Biology
Abstract

Targeted therapies directed to tumor-associated antigens are being investigated for the treatment of cancer. However, there are few suitable animal models for testing the ability to target these tumor markers. Therefore, we have exploited mice transgenic for the human coxsackie and adenovirus receptor (hCAR) to establish a new model for transient expression of human tumor-associated antigens in the pulmonary vasculature. Systemic administration of Ad in hCAR mice resulted in an increase in transgene expression in the lungs compared to wild type mice, as determined using a luciferase reporter gene. To reduce transgene expression in the liver, the predominant organ of ectopic Ad localization and transgene expression following systemic administration, we utilized the endothelial-specific flt-1 promoter, which resulted in a further increased lung-to-liver ratio of luciferase expression. Administration of an adenoviral vector encoding the tumor-associated antigen carcinoembryonic antigen (CEA) under transcriptional control of the flt-1 promoter resulted in selective expression of this antigen in the pulmonary vasculature of hCAR mice. Feasibility of targeting to expressed CEA was subsequently demonstrated using adenoviral vectors pre-incubated with a bifunctional adapter molecule recognizing this tumor-associated antigen, thus demonstrating utility of this transient transgenic animal model.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results